Innovation Pharmaceuticals Inc. (IPIX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.25 Million USD | 62.18% |
| 2022 | -3.3 Million USD | 60.29% |
| 2021 | -8.32 Million USD | -133.63% |
| 2020 | -3.56 Million USD | -365.23% |
| 2019 | 1.34 Million USD | 434.08% |
| 2018 | -402 Thousand USD | 81.03% |
| 2017 | -2.11 Million USD | 50.58% |
| 2016 | -4.28 Million USD | 32.87% |
| 2015 | -6.38 Million USD | -115.37% |
| 2014 | -2.96 Million USD | -372.31% |
| 2013 | 1.08 Million USD | -72.88% |
| 2012 | 4.01 Million USD | 797.31% |
| 2011 | 447.65 Thousand USD | -69.36% |
| 2010 | 1.46 Million USD | 400.54% |
| 2009 | 291.93 Thousand USD | 506.42% |
| 2008 | 48.14 Thousand USD | 508.07% |
| 2007 | -11.79 Thousand USD | -36.65% |
| 2006 | -8633.00 USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -626 Thousand USD | 49.92% |
| 2023 Q4 | -1.25 Million USD | 21.58% |
| 2023 Q2 | -2.03 Million USD | 19.38% |
| 2023 Q1 | -2.51 Million USD | 23.81% |
| 2023 FY | -1.25 Million USD | 62.18% |
| 2023 Q3 | -1.59 Million USD | 21.48% |
| 2022 Q4 | -3.3 Million USD | 59.93% |
| 2022 Q1 | -9.37 Million USD | -12.63% |
| 2022 FY | -3.3 Million USD | 60.29% |
| 2022 Q2 | -9.33 Million USD | 0.42% |
| 2022 Q3 | -8.24 Million USD | 11.62% |
| 2021 Q4 | -8.32 Million USD | 24.69% |
| 2021 FY | -8.32 Million USD | -133.63% |
| 2021 Q2 | -6.16 Million USD | -21.66% |
| 2021 Q1 | -5.07 Million USD | -42.34% |
| 2021 Q3 | -11.05 Million USD | -79.17% |
| 2020 Q2 | 2.35 Million USD | 41.99% |
| 2020 Q4 | -3.56 Million USD | -318.13% |
| 2020 Q1 | 1.65 Million USD | 23.23% |
| 2020 Q3 | 1.63 Million USD | -30.51% |
| 2020 FY | -3.56 Million USD | -365.23% |
| 2019 Q4 | 1.34 Million USD | -7.63% |
| 2019 FY | 1.34 Million USD | 434.08% |
| 2019 Q3 | 1.45 Million USD | 14.13% |
| 2019 Q1 | 1.71 Million USD | 526.87% |
| 2019 Q2 | 1.27 Million USD | -25.76% |
| 2018 Q3 | 686 Thousand USD | 159.19% |
| 2018 Q2 | -1.15 Million USD | -27.22% |
| 2018 Q1 | -911 Thousand USD | 57.01% |
| 2018 FY | -402 Thousand USD | 81.03% |
| 2018 Q4 | -402 Thousand USD | -158.6% |
| 2017 Q1 | -3.53 Million USD | 17.58% |
| 2017 FY | -2.11 Million USD | 50.58% |
| 2017 Q4 | -2.11 Million USD | 40.99% |
| 2017 Q3 | -3.59 Million USD | -95.48% |
| 2017 Q2 | -1.83 Million USD | 48.02% |
| 2016 Q2 | -4.16 Million USD | 27.66% |
| 2016 Q4 | -4.28 Million USD | -29.43% |
| 2016 Q3 | -3.31 Million USD | 20.38% |
| 2016 FY | -4.28 Million USD | 32.87% |
| 2016 Q1 | -5.75 Million USD | 9.96% |
| 2015 Q2 | -5.42 Million USD | -6.98% |
| 2015 FY | -6.38 Million USD | -115.37% |
| 2015 Q4 | -6.38 Million USD | 27.26% |
| 2015 Q1 | -5.07 Million USD | -70.97% |
| 2015 Q3 | -8.78 Million USD | -61.88% |
| 2014 Q3 | -3.12 Million USD | -235.99% |
| 2014 Q2 | -930.28 Thousand USD | -58.58% |
| 2014 Q1 | -586.62 Thousand USD | -153.86% |
| 2014 Q4 | -2.96 Million USD | 5.11% |
| 2014 FY | -2.96 Million USD | -372.31% |
| 2013 Q2 | 3.82 Million USD | -2.5% |
| 2013 FY | 1.08 Million USD | -72.88% |
| 2013 Q3 | 2.96 Million USD | -22.38% |
| 2013 Q4 | 1.08 Million USD | -63.28% |
| 2013 Q1 | 3.91 Million USD | -2.42% |
| 2012 Q2 | -697.52 Thousand USD | -541.27% |
| 2012 FY | 4.01 Million USD | 797.31% |
| 2012 Q4 | 4.01 Million USD | 1.67% |
| 2012 Q3 | 3.95 Million USD | 666.42% |
| 2012 Q1 | 158.07 Thousand USD | -64.69% |
| 2011 Q2 | 344.4 Thousand USD | -82.54% |
| 2011 FY | 447.65 Thousand USD | -69.36% |
| 2011 Q1 | 1.97 Million USD | 34.99% |
| 2011 Q4 | 447.65 Thousand USD | 8.89% |
| 2011 Q3 | 411.12 Thousand USD | 19.37% |
| 2010 Q3 | 1.03 Million USD | 69.25% |
| 2010 FY | 1.46 Million USD | 400.54% |
| 2010 Q4 | 1.46 Million USD | 41.47% |
| 2010 Q2 | 610.28 Thousand USD | 42.03% |
| 2010 Q1 | 429.67 Thousand USD | 47.18% |
| 2009 Q1 | 118.78 Thousand USD | 146.75% |
| 2009 Q3 | 239.31 Thousand USD | 51.27% |
| 2009 Q2 | 158.19 Thousand USD | 33.18% |
| 2009 FY | 291.93 Thousand USD | 506.42% |
| 2009 Q4 | 291.93 Thousand USD | 21.99% |
| 2008 Q4 | 48.14 Thousand USD | 10364.39% |
| 2008 Q3 | -469.00 USD | 0.0% |
| 2008 Q2 | -469.00 USD | 70.72% |
| 2008 Q1 | -1602.00 USD | 86.42% |
| 2008 FY | 48.14 Thousand USD | 508.07% |
| 2007 Q4 | -11.79 Thousand USD | 17.23% |
| 2007 FY | -11.79 Thousand USD | -36.65% |
| 2007 Q2 | -14.35 Thousand USD | 14.56% |
| 2007 Q3 | -14.25 Thousand USD | 0.7% |
| 2007 Q1 | -16.79 Thousand USD | 0.0% |
| 2006 FY | -8633.00 USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | -95319.847% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 122.13% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 102.921% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -400.761% |
| Rebus Holdings, Inc. | 305 Thousand USD | 509.836% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 80.173% |
| Qrons Inc. | 351.42 Thousand USD | 455.693% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 300.847% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 102.878% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -6025.049% |
| Skye Bioscience, Inc. | -5.72 Million USD | 78.152% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 107.93% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 130.354% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 411.062% |
| SQZ Biotechnologies Company | -36.23 Million USD | 96.551% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 155.748% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 234.817% |
| Mesoblast Limited | 55.85 Million USD | 102.238% |
| Marizyme, Inc. | 18.56 Million USD | 106.732% |
| Genus plc | 190.6 Million USD | 100.656% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 155.908% |
| Pharming Group N.V. | 109.8 Million USD | 101.138% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 245.308% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 202.975% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 283.824% |
| ContraFect Corporation | -6.02 Million USD | 79.257% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 1028.409% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 208.185% |
| IMV Inc. | 7.67 Million USD | 116.296% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 122.719% |
| MultiCell Technologies, Inc. | 90.04 USD | 1388371.879% |
| ONE Bio Corp. | 9.04 Million USD | 113.827% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -70.305% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 109.655% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 191.376% |
| Q BioMed Inc. | 4.06 Million USD | 130.788% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 104.091% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 224.043% |
| Biomind Labs Inc. | 711.4 Thousand USD | 275.709% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 102.065% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 162.519% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 109.761% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 447.502% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 994.109% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 6391.841% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 156.767% |
| GB Sciences, Inc. | 1.74 Million USD | 171.538% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -580.131% |
| HST Global, Inc. | 96.79 Thousand USD | 1391.416% |
| CSL Limited | 10.52 Billion USD | 100.012% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 706.158% |
| Halberd Corporation | 144.72 Thousand USD | 963.731% |
| Enzolytics Inc. | 981.65 Thousand USD | 227.336% |
| Agentix Corp. | 37.63 Thousand USD | 3421.729% |
| Resverlogix Corp. | 6.45 Million USD | 119.377% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -85.711% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 99.938% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 97.341% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 117.678% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 146.149% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 85.86% |
| AVAX Technologies, Inc. | -5.9 Million USD | 78.825% |
| Zenith Capital Corp. | 10.06 Thousand USD | 12520.509% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.882% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 723.653% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 152.388% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 859.837% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -6723.889% |
| Kadimastem Ltd | -253.1 Thousand USD | -393.872% |
| Helix BioMedix, Inc. | -2.57 Million USD | 51.362% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 106.165% |
| BioStem Technologies, Inc. | 4.47 Million USD | 127.952% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 721.106% |
| LadRx Corporation | -2.03 Million USD | 38.619% |
| Cell Source, Inc. | 9.23 Million USD | 113.54% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 296.799% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 296.799% |
| NovAccess Global Inc. | 2.17 Million USD | 157.38% |
| Affymax, Inc. | -5.59 Million USD | 77.667% |
| Itoco Inc. | 228.3 Thousand USD | 647.513% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 1019.192% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 125.217% |
| Mobile Lads Corp. | 484.23 Thousand USD | 358.141% |
| CytoDyn Inc. | 20.26 Million USD | 106.169% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -193099.382% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -13386.773% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 116.221% |
| SYBLEU INC | 473.71 Thousand USD | 363.872% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 128.046% |
| International Stem Cell Corporation | 2.59 Million USD | 148.263% |
| Bioxytran, Inc. | 1.89 Million USD | 165.827% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 2102.788% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 157.316% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 136.401% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 114.615% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 261.79% |
| Neutra Corp. | 52.18 Thousand USD | 2495.233% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 49.779% |
| PureTech Health plc | -167.19 Million USD | 99.252% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -410.396% |
| IXICO plc | -4.44 Million USD | 71.876% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 109.456% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 102.279% |
| CSL Limited | 10.52 Billion USD | 100.012% |
| Cellectis S.A. | -43.81 Million USD | 97.147% |